MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.24
−0.65%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.55
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$2.85
- EPS estimate
- -$0.55
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -93.4%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $43
- PT range
- $29 – $56
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.55 | -$2.85 | Miss -419.53% | — |
| May 6, 2026 | -$0.51 | -$0.47 | Beat 7.84% | — |
| Mar 12, 2026 | -$0.52 | -$0.40 | Beat 22.52% | — |
| Aug 12, 2025 | -$0.78 | -$0.66 | Beat 15.38% | — |
| Feb 12, 2025 | -$1.00 | -$0.98 | Beat 2.00% | — |
| May 9, 2024 | -$0.68 | -$0.70 | Miss -2.94% | — |
| Mar 21, 2024 | -$0.85 | -$0.61 | Beat 28.24% | — |
| May 15, 2023 | -$0.71 | -$0.51 | Beat 28.17% | — |
| Mar 15, 2023 | $1.72 | -$1.74 | Miss -201.16% | — |
| Jun 30, 2022 | — | -$0.35 | — | — |
| Mar 31, 2022 | — | -$0.41 | — | — |
| Dec 31, 2021 | — | -$0.18 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026